Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Michael P. Kolinsky
Prostate-Specific Antigen Decline After 4 Weeks of Treatment With Abiraterone Acetate and Overall Survival in Patients With Metastatic Castration-Resistant Prostate Cancer
European Urology
Urology
Related publications
Mp50-20 Impact of Abiraterone Acetate in Prostate Specific Antigen Trial Update: Effect of Abiraterone Acetate and Low Dose Prednisone on Prostate-Specific Antigen and Radiographic Disease Progression in Patients With Non-Metastatic Castration-Resistant Prostate Cancer
Journal of Urology
Urology
Enzalutamide and Abiraterone in the Treatment of Metastatic Castration-Resistant Prostate Cancer After Chemotherapy
Klinicka Onkologie
Oncology
Prostate-Specific Membrane Antigen–Directed Therapy for Metastatic Castration-Resistant Prostate Cancer
Cancer Journal
Cancer Research
Oncology
Abiraterone in Metastatic Castration-Resistant Prostate Cancer: Efficacy and Safety in Unselected Patients
Cancer Treatment and Research Communications
Cancer Research
Oncology
A Phase 2 Trial of Abiraterone Acetate Without Glucocorticoids for Men With Metastatic Castration-Resistant Prostate Cancer
Cancer
Cancer Research
Oncology
Predictive Factors of Response and Overall Survival in Patients With Castration-Resistant Metastatic Prostate Cancer Undergoing177Lu-Psma Therapy
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
A Prognostic Model for Stratifying Clinical Outcomes in Chemotherapy-Naive Metastatic Castration-Resistant Prostate Cancer Patients Treated With Abiraterone Acetate
Canadian Urological Association Journal
Urology
Treatment Sequences, Patient Characteristics, and Overall Survival of Patients With Post-Docetaxel Metastatic Castration-Resistant Prostate Cancer in the Community Setting
Value in Health
Medicine
Health Policy
Public Health
Occupational Health
Environmental
Radiotherapy in Metastatic Castration Resistant Prostate Cancer Patients With Oligo-Progression During Abiraterone-Enzalutamide Treatment: A Mono-Institutional Experience
Radiation Oncology
Nuclear Medicine
Radiology
Imaging
Oncology
